RxDoctor Payments Data

Deborah Galloway, MD

Neurology · Stony Brook, NYNPI 1346292869

Payments from drug & device makers

$11,115in general payments, 2019–2025

Across 485 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lundbeck LLC$940
  • Neurocrine Biosciences, Inc.$811
  • Pfizer$696
  • Amneal Pharmaceuticals LLC$478
  • AstraZeneca$367
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$11,095100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,115 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$237,061
Medicare patients
676
Services billed
2,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$73,316
BotoxOnabotulinumtoxina28$35,729
Nurtec OdtRimegepant Sulfate13$22,324
Emgality PenGalcanezumab-Gnlm11$7,278
Memantine Hcl ErMemantine Hcl15$2,643
Carbidopa-LevodopaCarbidopa/Levodopa125$1,536
Donepezil Hcl169$1,242
Zolmitriptan OdtZolmitriptan15$1,199
Galantamine Hbr26$1,044
Gabapentin102$939
Propranolol Hcl ErPropranolol Hcl26$918
Duloxetine Hcl71$884
Carbidopa-Levodopa ErCarbidopa/Levodopa37$826
Levetiracetam27$715
Sumatriptan Succinate13$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$175$73,31611 claims
AbbVieBotox$3,234$35,72928 claims
PfizerNurtec Odt$696$22,32413 claims
Upsher-smith Laboratories LLCTopiramate$27$24534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →